Electronic nose for breath analysis after curative Surgery to detect distant metastases or locoregional recurrence of colon cancer
- Conditions
- Patients undergoing curative treatment for CRC
- Registration Number
- NL-OMON22434
- Lead Sponsor
- •The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. •The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.
- Brief Summary
Steenhuis, E.G.M., Schoenaker, I.J.H., de Groot, J.W.B., Fiebrich, H.B., de Graaf, J.C., Brohet, R.M., van Dijk, J.D., van Westreenen, H.L., Siersema, P.D., de Vos tot Nederveen Cappel, W.H. (2020). Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study. European Journal of Surgical Oncology, 46(11), 2068-2073
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1184
1. Follow-up patients with an intentional curative treatment of CRC stage I to IV
• a CRC treated with curative intent by means of a colorectal resection
• curative treatment of synchronous metastases in combination with colorectal resection
• curatively treated metachronous metastases, after colorectal resection
2. Age = 18 years.
1. Not proficient in Dutch
2. Reason to believe that the patient cannot perform a breath test
3. CRC not treated curatively
4. CRC pT1N0Mx / pT1NxMx (patients receiving endoscopic control only)
5. Local (surgical or endoscopic) resection
6. Active treatment of other malignancies within the past three months
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the diagnostic accuracy of eNose in the detection of recurrent CRC
- Secondary Outcome Measures
Name Time Method